Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status

European Journal of Pharmacology

Volumn 588, Issue 2-3, 2008, Pages 158-164

  Thasni, Karedath Abdul Aziz ^a   Rojini, Gopakumaran ^a   Rakesh, S Nair ^a   Ratheeshkumar, Thankappan ^a   Babu, Mani Shankar ^a   Srinivas, Gopala ^b   Banerji, Asoke ^c   Srinivas, Priya ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^b SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^c Centre for Biotechnology   (India)

Author keywords

Apoptosis; BRCA1; Estrogen receptor; Genistein; Ovarian cancer

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; CASPASE 8; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FAS ANTIGEN; GENISTEIN;

APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; OVARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; ESTROGEN RECEPTOR ALPHA; FEMALE; GENES, BRCA1; GENISTEIN; HUMANS; OVARIAN NEOPLASMS; RESPONSE ELEMENTS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 44949133877     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.041     Document Type: Article

References (35)

1. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
2. Annab L.A., Hawkins R.E., and Solomon G. Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line. Breast Cancer Res. 2 (2000) 139-148
3. Baer R., and Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12 (2002) 86-91
4. Bardin A., Boulle N., Lazennec G., Vignon F., and Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr.-Relat. Cancer 11 (2004) 537-551
5. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J., and Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54 (1998) 105-112
6. Cabanes A., Wang M., Olivo S., DeAssis S., Gustafsson J.A., Khan G., and Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 25 (2004) 741-748
7. Caetano B., Le Corre L., Chalabi N., Delort L., Bignon Y.J., and Bernard-Gallon D.J. Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines. Br. J. Nutr. 95 (2006) 406-413
8. Chen B., Gajdos C., Dardes R., Kidwai N., Johnston S.R., Dowsett M., and Jordan V.C. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Int. J. Oncol. 27 (2005) 327-335
9. Constantinou A., Mehta R., Runyan C., Rao K., Vaughan A., and Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J. Nat. Prod. 58 (1995) 217-225
10. Fan S., Ma Y.X., Wang C., Yuan R.Q., Meng Q., Wang J.A., Erdos M., Goldberg I.D., Webb P., Kushner P.J., Pestell R.G., and Rosen E.M. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20 (2001) 77-87
11. Fan S., Ma Y.X., Wang C., Yuan R.Q., Meng Q., Wang J.A., Erdos M., Goldberg I.D., Webb P., Kushner P.J., Pestell R.G., and Rosen E.M. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 62 (2002) 141-151
12. Fan S., Meng Q., Auborn K., Carter T., and Rosen E.M. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br. J. Cancer 94 (2006) 407-426
13. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 (2003) 1169-1173
14. Fotsis T., Pepper M.S., Aktas E., Breit S., Rasku S., Adlercreutz H., Wahala K., Montesano R., and Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 57 (1997) 2916-2921
15. Harkin D.P., Bean J.M., Miklos D., Song Y.H., Truong V.B., Englert C., Christians F.C., Ellisen L.W., Maheswaran S., Oliner J.D., and Haber D.A. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97 (1999) 575-586
16. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y., Ogata H., and Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276 (2001) 14537-14540
17. Husain A., He G., Venkatraman E.S., and Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58 (1998) 1120-1123
18. Jeune M.A., Kumi-Diaka J., and Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J. Med. Food 8 (2005) 469-475
19. Ju Y.H., Allred C.D., Allred K.F., Karko K.L., Doerge D.R., and Helferich W.G. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J. Nutr. 131 (2001) 2957-2962
20. Kuzumaki T., Kobayashi T., and Ishikawa K. Genistein induces p21 (Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun. 251 (1998) 291-295
21. Lamartiniere C.A. Protection against breast cancer with genistein: a component of soy. Am. J. Clin. Nutr. 71 (2000) 1708S-1709S
22. Manna S.K., and Aggarwal B.B. Lipopolysaccharide inhibits TNF-induced apoptosis: role of nuclear factor-kappa B activation and reactive oxygen intermediates. J. Immunol. 162 (1999) 1510-1518
23. Markovits J., Linassier C., Fosse P., Couprie J., Pierre J., Jacquemin-Sablon A., Saucier J.M., Le Pecq J.B., and Larsen A.K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49 (1989) 5111-5117
24. Matsuda H., Shimoda H., Morikawa T., and Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg. Med. Chem. Lett. 11 (2001) 1839-1842
25. Messina M., and Barnes S. The role of soy products in reducing risk of cancer. J. Natl. Cancer Inst. 83 (1991) 541-546
26. Messina M.J., and Loprinzi C.L. Soy for breast cancer survivors: a critical review of the literature. J. Nutr. 131 (2001) 3095S-4108S
27. Moynahan M.E., Cui T.Y., and Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61 (2001) 4842-4850
28. Nomoto S., Arao Y., Horiguchi H., Ikeda K., and Kayama F. Oestrogen causes G2/M arrest and apoptosis in breast cancer cells MDA-MB-231. Oncol. Rep. 9 (2002) 773-776
29. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., and Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
30. Srinivas G., Anto R.J., Srinivas P., Vidhyalakshmi S., Senan V.P., and Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly (ADP-ribose) polymerase cleavage and activation of caspase-9. Eur. J. Pharmacol. 473 (2003) 117-125
31. Srinivas G., Annab L.A., Gopinath G., Banerji A., and Srinivas P. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Mol. Carcinog. 39 (2004) 15-25
32. Sylvain V., Lafarge S., and Bignon Y.J. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int. J. Oncol. 20 (2002) 845-853
33. Thasni, K.A., Rakesh, S., Rojini, G., Ratheeshkumar, T., Srinivas, G., Srinivas, Priya. Estrogen dependent cell signaling and apoptosis in brca1 blocked bg1 ovarian cancer cells in response to plumbagin and other standard chemotherapeutic agents. (Annals of Oncology Advance Access published January 10, 2008).
34. Zheng L., Annab L.A., Afshari C.A., Lee W.H., and Boyer T.G. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9587-9592
35. Zhou C., Smith J.L., and Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22 (2003) 2396-2404